Adagene Price Target Maintained With a $9.00/Share by Chardan Capital

What happened

Chardan Capital maintained its Buy rating on Adagene and kept its price target at $9.00 per share, according to ratings actions reported by Benzinga.

Confirmed

Global impact / market context

A repeated Buy rating and unchanged $9.00 target signal that this analyst still expects Adagene shares to rise toward that level, which matters to investors holding or considering the stock because it is a public view on future value.

Analyst inference

Analyst ratings and price targets are common inputs for investors judging a stock, but they reflect one firm's view rather than company results. Adagene investors may compare this target with the current share price to judge expected return.

Analyst inference

What to watch

1. Watch whether Chardan Capital later changes its Buy rating or its $9.00 per share price target for Adagene. Confirmed
2. Adagene could report company updates that lead analysts to revise ratings or price targets, so follow any such announcements. Proposed
3. Compare Adagene's actual share price with the $9.00 target to see whether investors appear to share the analyst's expected return. Analyst inference

Evidence

• Original source link unavailable